Beyond clinical trials: CDK4/6 inhibitor efficacy predictors and nomogram model from real‐world evidence in metastatic breast cancer
This real-world study highlights the ample efficacy and reasonable safety of combined CDK4/6i and ET in patients with HR+ MBC. Individualized treatment decisions and ongoing safety monitoring are important to optimize the therapeutic benefit of CDK4/6i treatment.
Authors
- Huawu Xiao
- Zhengrong Shui
- Zheyu Hu
- Binliang Liu (ORCID: https://orcid.org/0000-0002-3692-2272)
- Hui Wu (ORCID: https://orcid.org/0000-0002-1620-5321)
- Jing Li (ORCID: https://orcid.org/0000-0002-6099-8349)
- Liping Liu (ORCID: https://orcid.org/0000-0003-2943-055X)
- Jun Lü (ORCID: https://orcid.org/0000-0002-7343-9706)
- Ning Xie (ORCID: https://orcid.org/0000-0002-4628-2299)
- Jianxiang Gao (ORCID: https://orcid.org/0009-0004-1184-1523)
- Can Tian (ORCID: https://orcid.org/0000-0002-3675-4627)
- Min Cao (ORCID: https://orcid.org/0000-0002-0909-8871)
- Xiaohong Yang (ORCID: https://orcid.org/0000-0002-8707-8411)
- Xu-Ran Zhao (ORCID: https://orcid.org/0009-0000-3617-684X)
- Xuming Hu
- Yu Tang
- Quchang Ouyang
Institutions
- Central South University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Hunan Cancer Hospital (CN)
- Third Xiangya Hospital (CN)
Publication Details
- Journal
- Cancer Innovation
- Published
- 2024-10-25
- DOI
- https://doi.org/10.1002/cai2.143
- Citations
- 5
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Hunan Province